cliffwatch

relacorilant · Corcept Therap · NDA 220641

Lifyorli (Copackaged)

Earliest generic entry, as listed
22 Dec 2041

Blocked by patent: US 12152028, US 12152028, US 12152028.

Listed patents · 20 unexpired

PatentClaimsExpires
US 12152028product, use U-445922 Dec 2041
US 12152028product, use U-445822 Dec 2041
US 12152028product, use U-445722 Dec 2041
US 11285145use U-445826 May 2041
US 11285145use U-445726 May 2041
US 11285145use U-445926 May 2041
US 12589094use U-445926 May 2041
US 12589094use U-445726 May 2041
US 12589094use U-445826 May 2041
US 11464764product14 Apr 2040
US 11925626product18 Dec 2039
US 12514849product18 Dec 2039
US 10456392use U-445724 May 2033
US 11576907substance, product, use U-445824 May 2033
US 11576907substance, product, use U-445724 May 2033
US 11576907substance, product, use U-445924 May 2033
US 8859774substance, product24 May 2033
US 9273047use U-445924 May 2033
US 9273047use U-445724 May 2033
US 9273047use U-445824 May 2033

Exclusivities · 1 unexpired

NCEnew chemical entity (5 years)25 Mar 2031

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
220641 · 001 · RLDcapsule, oral100MG;25MG22 Dec 2041